Initial focus will be on tools to help cancer diagnosis.

Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.


The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products. The resulting microarray-based tests will, the companies report, enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.

Previous articleKineMed to Validate New Drug Applications for Merck KGaA
Next articleEpix Achieves $0.5M Milestone in Collaboration with Cystic Fibrosis Foundation Therapeutics